Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

NCT03653052 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Oesophageal Cancer

Interventions

DRUG: Durvalumab

Sponsor

Simon C Pacey, MD

Collaborators

[object Object]